The Cystic Fibrosis Foundation today announced an unprecedented acceleration and expansion of its research, care and patient programs for the CF community. This action is possible as a result of the sale of the Foundation's royalty rights to CF treatments developed by Vertex Pharmaceuticals Inc. The Foundation received $3.3 billion from the sale to Royalty Pharma.
Site Search
Showing 1 - 10 of 60 results
News
|
Nov. 2, 2009
|
3 min read
News
|
Nov. 19, 2014
|
3 min read
The Cystic Fibrosis Foundation awarded nearly $700,000 to Calibr, the drug discovery and development arm of Scripps Research, to screen for a compound that could be used to treat Burkholderia cepacia complex infections.
News
|
Jan. 14, 2020
|
2 min read
Press Release
|
Jan. 12, 2006
|
6 min read
News
|
Nov. 19, 2014
|
3 min read
The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.
News
|
Aug. 7, 2018
|
3 min read
News
|
Aug. 31, 2012
|
1 min read
Today Vertex Pharmaceuticals Inc. announced the two next-generation CFTR modulator candidates that will progress into Phase 3 clinical trials.
News
|
Jan. 31, 2018
|
4 min read
The Cystic Fibrosis Foundation awarded Talee Bio Inc. up to $4.5 million to develop methods for delivering potential gene therapy treatments to the lungs.
News
|
Jan. 24, 2019
|
2 min read
News
|
May 24, 2010
|
2 min read